We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Long Term Clinical Data from PISCES Stroke Trial
News

Long Term Clinical Data from PISCES Stroke Trial

Long Term Clinical Data from PISCES Stroke Trial
News

Long Term Clinical Data from PISCES Stroke Trial

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Long Term Clinical Data from PISCES Stroke Trial"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ReNeuron Group plc provides a further and final update on the PISCES Phase I clinical trial of its CTX stem cell therapy for disabled stroke patients.

Long term follow-up data out to at least 24 months in all patients treated in the PISCES study are
being presented by the clinical team from Glasgow’s Southern General Hospital on 19th April in a
platform presentation at the 2015 European Stroke Organization Conference (ESOC), taking place in Glasgow. The data are being presented ahead of submission for publication in a peer-reviewed clinical journal later this year.

There have been no cell-related or immunological adverse events reported in any of the eleven
patients treated in the study (across the four ascending dose levels). Adverse events reported were related only to the implantation procedure or the patient’s underlying medical condition.

Improvements in neurological status and limb function compared to pre-treatment baseline
performance were observed within three months of treatment and maintained throughout long term follow-up. Improvements in the National Institutes of Health Stroke Scale (NIHSS) were seen in all dose groups. The NIHSS is a measure used to objectively quantify the impairment caused by a stroke.

For all subjects, the median baseline score was 7. This improved to 5 at 3 months and was sustained at 2 years follow up with a median score of 5 (p=0.002).

Other measures of neuromuscular disability were supportive of the NIHSS improvement. Mean
Ashworth Scale scores, a measure of limb spasticity, were 18.1 and 9.7 (affected upper and lower limb, respectively) at baseline, which improved to 15.7 and 7.8 at 3 months and 16.1 and 6.5 at 2 years.

Improvements in scores on the Barthel Index (a measure of activities of daily living) were also consistent with the neuromuscular score changes with a median value of 12 at baseline, 14 at 3 months and 14 at 2 years.

The Company is currently conducting a UK multi-site Phase II clinical trial (PISCES II) to examine the efficacy of its CTX stem cell treatment in patients disabled by an ischaemic stroke. As a result of observed good safety profile of the treatment, the highest cell dose from the PISCES study is being used in the ongoing Phase II study.

As with the PISCES study, the Phase II clinical trial involves a single, one-off injection of CTX cells into the brain. Subject to patient recruitment, initial data from this study are expected around the end of this year.

Olav Hellebø, Chief Executive Officer of ReNeuron, said: “We are delighted to report long term data from all of the stroke patients treated in the PISCES study at this year’s ESOC meeting. The data confirm the good safety profile of our CTX stem cell treatment in this setting and it is particularly gratifying to see that the functional improvements previously observed in the patients against baseline measurements have been maintained in long term follow up. We look forward to reporting data from our ongoing Phase II study with CTX in disabled stroke patients in due course.”

Professor Keith Muir, SINAPSE Professor of Clinical Imaging, Division of Clinical Neurosciences at the University of Glasgow, and Principal Investigator of the PISCES study, said: “We continue to be both pleased and encouraged by the data from the PISCES study. The long term follow-up data continue to demonstrate the safety and tolerability of the CTX treatment. The evidence of functional improvement warrant further investigation and, in this regard, we are delighted to be a principal participating centre in the ongoing Phase II efficacy study with CTX.”

Advertisement